UY36701A - Tratamiento contra el cáncer por manipulación de la microflora comensal - Google Patents
Tratamiento contra el cáncer por manipulación de la microflora comensalInfo
- Publication number
- UY36701A UY36701A UY0001036701A UY36701A UY36701A UY 36701 A UY36701 A UY 36701A UY 0001036701 A UY0001036701 A UY 0001036701A UY 36701 A UY36701 A UY 36701A UY 36701 A UY36701 A UY 36701A
- Authority
- UY
- Uruguay
- Prior art keywords
- microflora
- comensal
- handling
- against cancer
- treatment against
- Prior art date
Links
- 244000005706 microflora Species 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000011278 co-treatment Methods 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos de tratamiento y/o prevención del cáncer por manipulación de la microflora comensal. En particular, la cantidad, identidad, presencia, y/o relación de la microflora (por ejemplo, microflora del intestino) en un sujeto se manipula para facilitar uno o más co-tratamientos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562169112P | 2015-06-01 | 2015-06-01 | |
US201562248741P | 2015-10-30 | 2015-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36701A true UY36701A (es) | 2016-12-30 |
Family
ID=57441608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036701A UY36701A (es) | 2015-06-01 | 2016-06-02 | Tratamiento contra el cáncer por manipulación de la microflora comensal |
Country Status (18)
Country | Link |
---|---|
US (4) | US9855302B2 (es) |
EP (1) | EP3303401A4 (es) |
JP (2) | JP2018521013A (es) |
KR (2) | KR20240059639A (es) |
CN (1) | CN107847530A (es) |
AU (1) | AU2016270750B2 (es) |
BR (1) | BR112017025813A2 (es) |
CA (1) | CA2987129A1 (es) |
CL (1) | CL2017003024A1 (es) |
HK (1) | HK1253064A1 (es) |
IL (1) | IL255940A (es) |
MX (1) | MX2017015473A (es) |
PE (1) | PE20180673A1 (es) |
RU (1) | RU2017141448A (es) |
TW (1) | TW201717975A (es) |
UY (1) | UY36701A (es) |
WO (1) | WO2016196605A1 (es) |
ZA (2) | ZA201707986B (es) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011209940B2 (en) | 2010-02-01 | 2015-08-20 | Mikrobex Inc. | Bacteriotherapy for clostridium difficile colitis |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
CA2889182A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
EP3395351A1 (en) | 2014-12-23 | 2018-10-31 | 4D Pharma Research Limited | Immune modulation |
SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
IL283877B (en) | 2015-05-06 | 2022-07-01 | Snipr Tech Ltd | Changing bacterial populations and microbiota adaptation |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MX2017016529A (es) | 2015-06-15 | 2018-03-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas. |
KR20180012846A (ko) | 2015-06-15 | 2018-02-06 | 4디 파마 리서치 리미티드 | 박테리아 균주를 함유한 조성물 |
LT3206700T (lt) | 2015-06-15 | 2019-08-26 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterijų kamienus |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
LT3209310T (lt) | 2015-11-20 | 2018-04-25 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
FR3045383B1 (fr) | 2015-12-18 | 2019-06-14 | Maat Pharma | Procede de lyophilisation d'un echantillon de microbiote fecal |
SG10201913557TA (en) | 2016-03-04 | 2020-02-27 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
GB201609811D0 (en) * | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
MX2019003447A (es) | 2016-09-27 | 2019-08-29 | Univ Texas | Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma. |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
EP3559257A1 (en) | 2016-12-22 | 2019-10-30 | Institut Gustave Roussy (IGR) | Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment |
IL296740B2 (en) * | 2016-12-23 | 2023-09-01 | Univ Keio | Preparations and methods for the induction of CD8-positive t-cells |
US11666646B2 (en) | 2016-12-26 | 2023-06-06 | National University Corporation Kobe University | Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor |
EP3570856A2 (en) * | 2017-01-18 | 2019-11-27 | Evelo Biosciences, Inc. | Methods of treating cancer |
WO2018145082A1 (en) * | 2017-02-06 | 2018-08-09 | New York University | Methods and compositions for treating and diagnosing pancreatic cancers |
WO2018171555A1 (en) * | 2017-03-20 | 2018-09-27 | Crown Bioscience Inc. (Taicang) | Use of gut microbiota composition in immunotherapy |
EP3630136B1 (en) | 2017-05-22 | 2021-04-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
WO2018226690A1 (en) | 2017-06-05 | 2018-12-13 | The University Of Chicago | Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof |
CN111032061A (zh) | 2017-06-14 | 2020-04-17 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
TW201919670A (zh) | 2017-06-14 | 2019-06-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
US10792314B2 (en) * | 2017-07-05 | 2020-10-06 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using Bifidobacterium animalis ssp. lactis |
AU2018316343A1 (en) * | 2017-08-11 | 2020-02-13 | Genentech, Inc. | Anti-CD8 antibodies and uses thereof |
US20190175560A1 (en) * | 2017-12-01 | 2019-06-13 | Shepherd Therapeutics, Inc. | Mebendazole cancer therapies and methods of use |
WO2019141622A1 (en) * | 2018-01-17 | 2019-07-25 | Reponex Pharmaceuticals A/S | Compositions for eliminating bacterial promotors of colorectal cancer by intraluminal application |
KR20200110342A (ko) * | 2018-01-19 | 2020-09-23 | 4디 파마 리서치 리미티드 | 암을 치료하거나 예방하기 위한 조합 치료법 |
AU2019210005A1 (en) * | 2018-01-19 | 2020-08-06 | 4D Pharma Research Limited | Combination therapy for treating or preventing cancer |
KR20200110341A (ko) * | 2018-01-19 | 2020-09-23 | 4디 파마 리서치 리미티드 | 암을 치료하거나 예방하기 위한 조합 치료법 |
AU2019210002A1 (en) * | 2018-01-19 | 2020-08-13 | 4D Pharma Research Limited | Combination therapy for treating or preventing cancer |
CN110090230B (zh) * | 2018-01-30 | 2022-07-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
WO2019149859A1 (en) * | 2018-01-31 | 2019-08-08 | Universität Basel | Gut commensal bacteria for treatment of human colorectal cancer |
WO2019156234A1 (en) * | 2018-02-09 | 2019-08-15 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
KR20210018793A (ko) * | 2018-03-28 | 2021-02-18 | 세레스 테라퓨틱스, 인코포레이티드 | 마이크로바이옴 조절에 의한 암 치료 |
KR101980525B1 (ko) * | 2018-04-12 | 2019-05-21 | 주식회사 지놈앤컴퍼니 | 락토코커스 락티스 gen3013 균주, 및 이를 포함하는 암의 예방 또는 치료용 조성물 |
WO2019232284A1 (en) * | 2018-05-30 | 2019-12-05 | Evolve Biosystems, Inc. | Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis |
JP7490554B2 (ja) * | 2018-06-14 | 2024-05-27 | 株式会社明治 | 免疫チェックポイント阻害療法を促進するための組成物 |
WO2020018668A1 (en) * | 2018-07-17 | 2020-01-23 | Ferring B.V. | Combination therapy comprising microbiota restoration therapy (mrt) compositions |
EP3597202A1 (en) * | 2018-07-20 | 2020-01-22 | Maat Pharma | Fecal microbiota composition, for use in reducing treatment-induced inflammation |
MX2021001394A (es) * | 2018-08-05 | 2021-04-12 | Da Volterra | Metodo para mejorar la eficacia de un agente anticanceroso. |
US20220000949A1 (en) * | 2018-09-25 | 2022-01-06 | National Cerebral And Cardiovascular Center | Antitumor effect potentiator |
CN109266766B (zh) * | 2018-10-10 | 2021-10-19 | 中国人民解放军第三0二医院 | 肠道微生物作为胆管细胞癌诊断标志物的用途 |
US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
WO2020122476A1 (ko) * | 2018-12-10 | 2020-06-18 | 한국식품연구원 | 락토바실러스 사케아이 wikim30을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
KR102069622B1 (ko) * | 2019-06-25 | 2020-01-23 | 한국식품연구원 | 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
KR102136772B1 (ko) * | 2018-12-10 | 2020-07-23 | 한국식품연구원 | 락토바실러스 사케아이 wikim30을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
CN110106104B (zh) * | 2019-03-19 | 2021-12-17 | 江南大学 | 假小链双歧杆菌ccfm1048、其组合物、发酵食品、用途、菌剂及其菌剂制备方法 |
IL265735A (en) * | 2019-03-31 | 2019-05-30 | Biomica | A microbial consortium and its uses |
CN111773377B (zh) * | 2019-04-04 | 2023-03-14 | 中南大学 | 阿尼芬净在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN110063970A (zh) * | 2019-04-30 | 2019-07-30 | 上海心脉途医疗科技有限公司 | 与irAE相关的肠道菌群及irAE的治疗和预防方法 |
CN111991427A (zh) * | 2019-05-07 | 2020-11-27 | 瑞微(深圳)生物科技有限公司 | 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用 |
CN110734888B (zh) * | 2019-09-17 | 2021-08-03 | 广州维生君生物科技有限公司 | Tim3人源单链抗体融合基因转化乳酸菌及其应用 |
EP4048778A4 (en) * | 2019-11-01 | 2024-02-21 | Uti Lp | USING THE POWER OF MICROBIOTA AND METABOLITES TO TREAT CANCER |
US20220378855A1 (en) * | 2019-12-20 | 2022-12-01 | Persephone Biosciences, Inc. | Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same |
WO2021146647A1 (en) * | 2020-01-17 | 2021-07-22 | Second Genome, Inc. | Methods and compositions for treating cancer |
CN111228315A (zh) * | 2020-02-27 | 2020-06-05 | 上海上药信谊药厂有限公司 | 抗肿瘤组合物 |
CN111096982B (zh) * | 2020-02-27 | 2023-09-12 | 上海上药信谊药厂有限公司 | 抗肿瘤组合物 |
GB202007452D0 (en) | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
NL2025863B1 (en) | 2020-06-19 | 2022-02-17 | Acad Medisch Ct | Fecal matter for treatment of cachexia |
WO2022045637A1 (ko) | 2020-08-28 | 2022-03-03 | 주식회사 리비옴 | 항종양 세균 균주, 및 이를 이용한 조성물 및 방법 |
KR20220028425A (ko) | 2020-08-28 | 2022-03-08 | 주식회사 리비옴 | 항종양 세균 균주, 및 이를 이용한 조성물 및 방법 |
KR102489493B1 (ko) * | 2020-08-31 | 2023-01-18 | 주식회사 리비옴 | 항암 활성을 갖는 락토바실러스 플란타룸 미생물, 그를 포함하는 조성물 및 그를 이용한 암 예방 또는 치료 방법 |
EP4240356A1 (en) | 2020-11-03 | 2023-09-13 | RDiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
KR102307603B1 (ko) * | 2020-11-13 | 2021-10-05 | 주식회사 비피도 | 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물 |
WO2022261382A1 (en) * | 2021-06-09 | 2022-12-15 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for determining responsiveness to immune checkpoint inhibitors (ici), increasing effectiveness of ici, and treating cancer |
CN115786156A (zh) * | 2021-09-10 | 2023-03-14 | 香港中文大学 | 用于结直肠肿瘤的预防、治疗或风险控制的组合物 |
WO2023118868A1 (en) * | 2021-12-21 | 2023-06-29 | Quadram Institute Bioscience | Bifidobacterium and compositions thereof for breast cancer treatment |
CN114344342B (zh) * | 2021-12-29 | 2023-06-30 | 广东南芯医疗科技有限公司 | 副干酪乳杆菌Lp. R3在制备预防或治疗肿瘤药物中的应用 |
WO2023141119A1 (en) * | 2022-01-18 | 2023-07-27 | The Regents Of The University Of California | Bacterial compositions and methods for treating cancer and immune diseases |
WO2024035638A1 (en) * | 2022-08-08 | 2024-02-15 | Cornell University | Methods for classifying and treating gastrointestinal tumors based on mycobiome analysis |
WO2024095156A1 (en) * | 2022-10-31 | 2024-05-10 | Probionova Sa | Bacteria strains for the treatment of urological disorders, their compositions and uses thereof |
CN117089490B (zh) * | 2023-08-11 | 2024-06-07 | 浙江大学 | 青春双歧杆菌basj001及应用 |
CN118001305B (zh) * | 2024-04-09 | 2024-06-11 | 山东中科嘉亿生物工程有限公司 | 长双歧杆菌jblc-141在制备改善副肿瘤性血小板增多症药物中的应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
JP2005089388A (ja) * | 2003-09-18 | 2005-04-07 | Biofuerumin Seiyaku Kk | 免疫賦活作用増強剤 |
GB0323039D0 (en) | 2003-10-01 | 2003-11-05 | Danisco | Method |
ES2427646T5 (es) * | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
US8444967B2 (en) | 2010-07-09 | 2013-05-21 | Master Supplements, Inc. | Treatment including prebiotic composition for use with probiotics |
MX2012005524A (es) * | 2009-11-11 | 2013-04-03 | Procter & Gamble | Cepa de probioticos bifidobacterium. |
US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
RS58405B1 (sr) | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
CN104415060A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
CA2965114A1 (en) | 2013-10-21 | 2015-04-30 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
EP2876167A1 (en) * | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
KR20170003692A (ko) * | 2014-05-15 | 2017-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료 |
-
2016
- 2016-06-01 TW TW105117266A patent/TW201717975A/zh unknown
- 2016-06-01 KR KR1020247013503A patent/KR20240059639A/ko active Search and Examination
- 2016-06-01 EP EP16804316.4A patent/EP3303401A4/en active Pending
- 2016-06-01 AU AU2016270750A patent/AU2016270750B2/en active Active
- 2016-06-01 WO PCT/US2016/035228 patent/WO2016196605A1/en active Application Filing
- 2016-06-01 BR BR112017025813A patent/BR112017025813A2/pt active Search and Examination
- 2016-06-01 CN CN201680031836.5A patent/CN107847530A/zh active Pending
- 2016-06-01 MX MX2017015473A patent/MX2017015473A/es unknown
- 2016-06-01 PE PE2017002514A patent/PE20180673A1/es unknown
- 2016-06-01 US US15/170,284 patent/US9855302B2/en active Active
- 2016-06-01 CA CA2987129A patent/CA2987129A1/en not_active Abandoned
- 2016-06-01 JP JP2017561803A patent/JP2018521013A/ja active Pending
- 2016-06-01 KR KR1020177037299A patent/KR102661603B1/ko active IP Right Grant
- 2016-06-01 RU RU2017141448A patent/RU2017141448A/ru unknown
- 2016-06-02 UY UY0001036701A patent/UY36701A/es not_active Application Discontinuation
-
2017
- 2017-09-28 US US15/718,735 patent/US20180015131A1/en not_active Abandoned
- 2017-11-23 ZA ZA2017/07986A patent/ZA201707986B/en unknown
- 2017-11-27 IL IL255940A patent/IL255940A/en unknown
- 2017-11-28 CL CL2017003024A patent/CL2017003024A1/es unknown
-
2018
- 2018-09-27 HK HK18112446.5A patent/HK1253064A1/zh unknown
-
2019
- 2019-02-22 US US16/282,517 patent/US20190183942A1/en not_active Abandoned
- 2019-11-19 ZA ZA2019/07641A patent/ZA201907641B/en unknown
-
2021
- 2021-09-21 JP JP2021153369A patent/JP2022000447A/ja active Pending
- 2021-11-02 US US17/517,084 patent/US20220296656A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2987129A1 (en) | 2016-12-08 |
PE20180673A1 (es) | 2018-04-19 |
HK1253064A1 (zh) | 2019-06-06 |
US20180015131A1 (en) | 2018-01-18 |
KR102661603B1 (ko) | 2024-04-29 |
US20190183942A1 (en) | 2019-06-20 |
AU2016270750B2 (en) | 2022-06-16 |
EP3303401A1 (en) | 2018-04-11 |
TW201717975A (zh) | 2017-06-01 |
ZA201907641B (en) | 2021-05-26 |
US20160354416A1 (en) | 2016-12-08 |
KR20240059639A (ko) | 2024-05-07 |
US20220296656A1 (en) | 2022-09-22 |
US9855302B2 (en) | 2018-01-02 |
CL2017003024A1 (es) | 2018-07-06 |
IL255940A (en) | 2018-01-31 |
ZA201707986B (en) | 2020-01-29 |
WO2016196605A1 (en) | 2016-12-08 |
MX2017015473A (es) | 2018-08-15 |
RU2017141448A3 (es) | 2019-11-19 |
JP2022000447A (ja) | 2022-01-04 |
BR112017025813A2 (pt) | 2018-08-14 |
CN107847530A (zh) | 2018-03-27 |
KR20180011262A (ko) | 2018-01-31 |
AU2016270750A1 (en) | 2017-12-14 |
JP2018521013A (ja) | 2018-08-02 |
RU2017141448A (ru) | 2019-07-15 |
EP3303401A4 (en) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36701A (es) | Tratamiento contra el cáncer por manipulación de la microflora comensal | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
PH12016501978A1 (en) | Treatment of nafld and nash | |
EA201892386A1 (ru) | Химерные нейротоксины | |
MX360041B (es) | Composiciones y metodos para el cuidado personal. | |
MX2019006821A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos. | |
DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
CL2021001256A1 (es) | Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470) | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
NZ729191A (en) | Methods and compositions comprising a ct20 peptide | |
RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
AU365961S (en) | Clasp | |
EA201691907A1 (ru) | Комбинированная терапия кураксинами | |
UA92840U (uk) | Дегідратаційно-дегреасингаційний розчин для пластинації анатомічних препаратів |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20221121 |